Patients with obesity-related heart failure who took semaglutide 2.4 mg weekly lost substantial weight and reported fewer symptoms after one year, but new imaging data show the drug rarely changed the structure of their hearts. The disconnect between how patients felt and what their echocardiograms revealed raises a pointed question: does weight loss from GLP-1 drugs actually reverse the cardiac damage that obesity causes, or does it simply mask the symptoms while the underlying problem persists?
Why symptom gains without structural heart change matter right now
The STEP-HFpEF trial, a randomized, double-blind, placebo-controlled study, showed that semaglutide 2.4 mg weekly improved patient-reported outcomes at 52 weeks. Scores on the Kansas City Cardiomyopathy Questionnaire, which measures symptoms and physical limitations, rose meaningfully compared with placebo, and exercise capacity also improved. Those results were strong enough that on September 19, 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending a Wegovy label update to reflect reduced heart failure symptoms and improved physical function.
Yet the imaging story tells a different tale. A prespecified echocardiography analysis published in the Journal of the American College of Cardiology examined paired scans from 491 participants, roughly 43% of the trial population. The primary outcome was change in left atrial volume, a marker that tends to enlarge when the heart struggles under chronic pressure overload from obesity. After 52 weeks of semaglutide, that marker did not meaningfully shrink.
The gap between symptom relief and structural stasis is not merely academic. Clinicians prescribing these drugs to heart failure patients need to know whether weight loss is buying time or buying a cure. If semaglutide eases breathlessness and fatigue primarily by reducing visceral fat and lowering the mechanical burden on the heart, rather than by reversing the thickened walls and stretched chambers that define the disease, then stopping the drug could mean symptoms return in full. That possibility has direct consequences for how long patients stay on therapy and how insurers justify coverage.
What the STEP-HFpEF and SELECT trials actually measured
The original STEP-HFpEF results, published in the New England Journal of Medicine, established semaglutide 2.4 mg weekly as the first GLP-1 receptor agonist to show clear benefits in heart failure with preserved ejection fraction linked to obesity. The trial’s dual primary endpoints, KCCQ clinical summary score and body weight, both favored semaglutide at 52 weeks. A companion trial, STEP-HFpEF DM, extended those findings to patients who also had type 2 diabetes, reporting similar improvements in heart failure symptoms and weight loss over the same period.
Separately, the SELECT trial tested semaglutide 2.4 mg in a different population: people with overweight or obesity and established cardiovascular disease but no diabetes. Over a mean follow-up of approximately 33 months, semaglutide reduced major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death. That trial offered the first hard-endpoint evidence that GLP-1 therapy can cut serious cardiac events in people whose primary risk factor is excess weight.
The contrast between these datasets is instructive. SELECT showed fewer heart attacks and strokes over nearly three years. The STEP-HFpEF echocardiography substudy showed no significant left atrial volume reduction after one year. One plausible reading is that the cardiovascular protection semaglutide provides operates through mechanisms, such as reduced inflammation, improved endothelial function, and lower metabolic stress, that do not register on a 12-month echocardiogram. Structural reverse remodeling of the heart may simply require more time than the trial allowed.
That hypothesis aligns with what cardiologists have observed in other settings. Weight loss from bariatric surgery, for example, can take 18 to 24 months to produce measurable reductions in left atrial size and left ventricular mass. If the same timeline applies to pharmacological weight loss, the STEP-HFpEF echo data may have been collected too early to capture changes that would eventually appear with continued therapy.
Gaps in the echo data and what patients should watch for next
Several limitations weaken any firm conclusion about semaglutide and cardiac remodeling. The echocardiography substudy captured paired scans from only 43% of the trial population. Whether the patients who underwent imaging were fully representative of the overall cohort is uncertain; people willing and able to return for repeat echocardiograms may differ in age, comorbidities, or disease severity from those who did not. If the imaging subset skewed toward milder or more advanced disease, true structural changes in other patients could have been diluted in the average.
In addition, left atrial volume, while clinically meaningful, is just one lens on heart structure. HFpEF is characterized by a complex mix of stiff ventricular muscle, microvascular dysfunction, and systemic inflammation. Semaglutide might improve diastolic function, pulmonary pressures, or myocardial strain without shrinking the atrium over a single year. Standard echocardiography can miss subtle shifts in these parameters, especially when images are collected across multiple centers with variable equipment and expertise.
The substudy also lacked long-term follow-up beyond 52 weeks. If meaningful reverse remodeling requires sustained weight loss and metabolic control over several years, the current dataset simply cannot answer whether semaglutide eventually reshapes the heart. Ongoing and planned extensions of GLP-1 cardiovascular trials will be critical to determine whether structural benefits emerge later or whether the primary gains remain symptomatic and event-based rather than anatomical.
For patients, the most practical question is how to interpret feeling better when scans look largely unchanged. One implication is that symptom relief on semaglutide should not lull anyone into abandoning other heart failure therapies. Guideline-directed medications, blood pressure control, sodium restriction, and regular physical activity remain foundational. Semaglutide appears to add to, not replace, these pillars of care.
Another implication is that treatment may need to be viewed as chronic rather than time-limited. If the drug’s benefits stem mainly from ongoing weight loss, lower blood pressure, and improved metabolic profiles, then stopping therapy could allow weight and symptoms to creep back, even if some modest structural improvements have occurred. Patients and clinicians will need to weigh the cost, side effects, and practical burdens of long-term injections against the quality-of-life and event-reduction benefits documented in STEP-HFpEF and SELECT.
Insurers and policymakers face their own calculus. The positive regulatory opinion on the Wegovy label underscores that symptom and functional gains are now recognized outcomes in obesity-related heart failure. Yet payers may still ask whether high-cost GLP-1 therapy meaningfully alters the natural history of HFpEF or primarily manages symptoms. More granular imaging data, including cardiac MRI and advanced echocardiographic measures, could help answer whether semaglutide is remodeling the disease or mainly relieving its hemodynamic consequences.
Until those answers arrive, a balanced message to patients is warranted. Semaglutide 2.4 mg weekly has been shown to improve how people with obesity-related HFpEF feel and function, and to reduce major cardiovascular events in high-risk individuals without diabetes. At the same time, current echocardiography data suggest that dramatic structural reversal of heart changes is not guaranteed within the first year of therapy. The drug should be seen as a powerful tool in a broader strategy that includes lifestyle change, standard heart failure medications, and close follow-up, rather than as a standalone fix that erases years of cardiac stress.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
